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Abstract
Background: PPARs exhibit anti-inflammatory capacities and are potential modulators of the
inflammatory response. We hypothesized that their expression and/or function may be altered in
cystic fibrosis (CF), a disorder characterized by an excessive host inflammatory response.
Methods: PPARα, β and γ mRNA levels were measured in peripheral blood cells of CF patients
and healthy subjects via RT-PCR. PPARα protein expression and subcellular localization was
determined via western blot and immunofluorescence, respectively. The activity of PPARα was
analyzed by gel shift assay.
Results: In lymphocytes, the expression of PPARα mRNA, but not of PPARβ, was reduced (-37%;
p < 0.002) in CF patients compared with healthy persons and was therefore further analyzed. A
similar reduction of PPARα was observed at protein level (-26%; p < 0.05). The transcription factor
was mainly expressed in the cytosol of lymphocytes, with low expression in the nucleus. Moreover,
DNA binding activity of the transcription factor was 36% less in lymphocytes of patients (p < 0.01).
For PPARα and PPARβ mRNA expression in monocytes and neutrophils, no significant differences
were observed between CF patients and healthy persons. In all cells, PPARγ mRNA levels were
below the detection limit.
Conclusion: Lymphocytes are important regulators of the inflammatory response by releasing
cytokines and antibodies. The diminished lymphocytic expression and activity of PPARα may
therefore contribute to the inflammatory processes that are observed in CF.
Background
Cystic fibrosis (CF) is a common inherited disease caused
by mutations in the gene encoding the cystic fibrosis
transmembrane conductance regulator (CFTR), which is
an epithelial chloride channel. The disorder affects multi-
ple organs and the phenotype is extremely heterogeneous.
However, CF morbidity and mortality are mainly due to
lung disease, which is characterized by an excessive host
inflammatory response. Although CF lung disease is gen-
erally considered to be a neutrophil-mediated disorder,
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recent studies suggest a potent role for lymphocytes in the
pathogenesis of the disease [1,2]. In addition, inflamma-
tory markers such as cytokines and eicosanoids are ele-
vated, not only locally, in the airways, but also
systemically, thus indicating a more generalized state of
inflammation in CF [3-5].
The nuclear factor-κB (NF-κB) and activated protein-1
(AP-1) transcription factors are key players in the inflam-
matory response by inducing the expression of cytokines,
chemokines, cell adhesion molecules and growth factors.
The actions of NF-κB and AP-1 can, however, be inhibited
by the Peroxisome Proliferator-Activated Receptors α and
γ (PPARs), which thereby exert anti-inflammatory proper-
ties [6-8]. PPARs are ligand-activated transcription factors
belonging to the nuclear hormone receptor super-family.
Fatty acids and eicosanoids are natural occurring PPAR
ligands [9,10]; fibrates and glitazones are more specific
synthetic activators for PPARα and γ, respectively. PPARs
regulate gene expression by heterodimerization with the
retinoid × receptor (RXR) and subsequent binding to spe-
cific DNA sequence elements, termed PPAR response ele-
ments (PPRE), in the promoter regions of their target
genes [11]. In addition, they can repress gene transcrip-
tion in a DNA-binding independent manner through
inhibition of other signaling pathways by protein-protein
interactions and cofactor competition [6,7,12]. At present,
three distinct PPAR isoforms have been identified, called
α, β and γ. PPARα and γ agonists decrease plasma concen-
trations of cytokines and acute phase proteins [13-15] and
induce anti-atherosclerotic effects [16,17] and are there-
fore able to influence the immune response. They also
seem to play a role in airway inflammation. Similarly,
PPARα and γ agonists have been reported to inhibit air-
way inflammation in a murine model of asthma [18] and
a model of airway infection [19] by inhibiting eosinophil,
lymphocyte and neutrophil influx into the lung.
Moreover, CF is associated with abnormalities in fatty acid
and eicosanoid metabolism. In addition to deficiencies in
essential fatty acids in plasma, increased release of arachi-
donic acid (AA) from the cell membrane and elevated lev-
els of pro-inflammatory eicosanoids in urine, blood and
airways have been reported [3,20-24]. Even cell mem-
brane compositions seem to be disturbed with increased
levels of AA and decreased levels of docosahexaenoic acid
(DHA) [25]. Fatty acids and derivatives can regulate the
actions of PPARs and an imbalance may therefore cause
inappropriate activation of PPARs.
In conclusion, we hypothesized that the expression of
PPARs, transcription factors with anti-inflammatory
capacities, is altered in CF. To check our hypothesis, we
measured PPARα, β and γ expression in peripheral blood
cells, which are important mediators of the inflammatory
response through the production and release of cytokines,
chemokines, and/or antibodies. We noticed differences
for PPARα levels in lymphocytes. Along the same line, an
altered PPARα activity was observed in lymphocytes,
which confirmed our hypothesis.
Materials and methods
Patients
This study was approved by the Ethics Committee of the
Frankfurt University Hospital. Patients with cystic fibrosis
were between 22 and 43 years old and were all affected by
lung disease. They had a stable condition and came for
routine check-up. The clinical characteristics of our
patients are represented in Table 1. An age-matched, gen-
der-mixed healthy control group was established for all
the experiments. Only healthy feeling volunteers, which
had not been ill for the past weeks, and which were free
from any detectable inflammation, infection or allergic
disease were selected for sampling. Due to time, technical
and sampling constraints, sample sizes vary between the
different experiments.
Measurement of IL-8 in plasma by ELISA
A commercial ELISA kit was used to measure IL-8 concen-
trations in plasma (R&D Systems, Germany). The instruc-
tions of the manufacturer were followed.
Measurement of sIL-2R in plasma by ELISA
A commercial ELISA kit was applied to measure soluble
IL-2 Receptor levels (R&D Systems, Germany). Prior to
use, plasma was diluted 1 to 4. The instructions of the
manufacturer were followed.
Isolation of peripheral lymphocytes and monocytes
To avoid circadian fluctuations of PPARs, blood samples
were always taken in the morning. Mononuclear cells
were isolated from whole blood by density gradient cen-
trifugation using Lymphoprep (Axis-Shield). After wash-
ing with PBS, monocytes were separated from
lymphocytes by magnetic sorting (Miltenyi Biotec, Ber-
gisch Gladbach, Germany). Cells were incubated with sat-
urating concentrations of anti-CD14+ monoclonal
antibodies conjugated with super paramagnetic particles
for 20 min. by 4°C. Subsequently, cells were resolved in
PBS (containing 5 mM EDTA and 0.5% BSA) and added
on top of a separation column. Unlabeled cells, i.e. lym-
phocytes, were collected through elution from the col-
umn. In order to isolate the monocytes, the separation
column was detached from the strong magnet and mono-
cytes were eluted. Purity was checked with May-Grünwald
Giemsa staining and was ≥ 97%.
Isolation of peripheral neutrophils
Density centrifugation using Polymorphprep™ solution
(Axis Shield, Heidelberg, Germany) enabled us to isolateRespiratory Research 2006, 7:104 http://respiratory-research.com/content/7/1/104
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neutrophils from whole blood. The mononuclear and
polymorphonuclear leucocytes were separated into 2 dis-
tinct bands, free from red blood cells. Neutrophils were
collected, washed with PBS and checked for purity via
May-Grünwald-Giemsa staining and had to be > 95%.
Reverse transcriptase – competitive multiplex PCR/real-
time PCR
Total RNA from monocytes, lymphocytes and neutrophils
was extracted with RNAzol B™ (Wak-Chemie, Germany)
and subjected to oligo(deoxythymidine)-primed first-
strand cDNA synthesis using the Superscript II Preampli-
fication System (Invitrogen, Karlsruhe, Germany). The
instructions of the manufacturers were followed.
Multiplex PCR (see Loitsch et al., 1999)[26]
Construction of internal standards
The cDNA derived from monocytes and lymphocytes was
amplified in the presence of a range of known concentra-
tions of internal standards (competitors). Internal stand-
ards for the PPARs and GAPDH were constructed as wild-
type fragments containing a deletion of nucleotides:
PPARα, β and γ cDNA with a 44, 41 and 106 bp deletion,
respectively and GAPDH cDNA with a 55 bp deletion. The
shortened fragments were obtained via PCR and the use of
following antisense primers: 5'-ATC ACA GAA GAC AGC
ATG GCC GTT CAG GTC CAA GTT TGC G-3' for PPARα,
5'-CTG CCA CAA TGT CTC GAT GTA GGA TGC TGC
GGG CCT TCT T-3' for PPARβ and 5'-TCA GCG GGA AGG
ACT TTA TGC ACT GGA GAT CTC CGC CAA C-3' for
PPARγ. The sense primers were the same as those used for
the multiplex PCR (see next paragraph). The fragments
were ligated in T-vectors (Promega) and the copy number
was calculated after spectrophotometric quantification.
Then, dilution series (1:3) of the internal standards were
established. The internal standards share identical primer
recognition sites with the wild-type target.
Competitive multiplex Polymerase Chain Reaction
Oligonucleotide primers for PCR were designed according
to published sequences: PPARα [GenBank Accession no.
Y07619]: sense 5'-TGCAGATCTCAAATCTCTGG-3', anti-
sense 5'-ATCACAGAAGACAGCATGGC-3', amplifying a
374 bp wild-type product; PPARβ [GenBank Accession
no. L07592]: sense 5'-TTCCAGAAGTGCCTGGCACT-3',
antisense 5'-CTGCCACAATGTCTCGATGT-3'; amplifying
a 275 bp wild-type product; PPARγ [GenBank Accession
no. D83136]: sense 5'-TCTCTCCGTAATGGAAGACC-3',
antisense 5'-TCTTTCCTGTCAAGATCGCC-3', amplifying
a 660 bp wild-type product and, GAPDH [GenBank Acces-
sion no. M33197]: sense 5'-ATCTTCCAGGAGCGA-
GATCC-3', antisense 5'-ACCACTGACACGTTGGCAGT-3',
amplifying a 502 bp wild-type product.
2–10 μl cDNA was added to a PCR master-mix, which
contained all the primers mentioned above. Next, the mix
was divided over a series of reaction tubes into which
known concentrations of internal standards were spiked.
Cycling conditions for PCR were as follows: 94°C for 3
minutes (1 cycle), followed by 40 cycles of 94°C, 58°C,
72°C, each for 45 seconds and a final extension phase at
72°C for 10 minutes (Trio-Thermoblock, Biometra).
Table 1: Clinical characteristics of cystic fibrosis patients.
Patient Age (years) Gender Genotype P.a.1 CRP FEV1 % pred2 FVC % pred2
13 3F d F 5 0 8 / R 5 5 3 x +0 , 9 5 8 9 1
2 25 M dF508/dF508 + 0,5 74 90
3 30 M dF508/dF508 + 0,7 42 72
4 34 M dF508/? + 0,3 59 80
5 37 M dF508/dF508 + 0,6 52 84
6 32 F dF508/dF508 + 2 60 75
7 26 F dF508/dF508 + 1,32 86 87
8 28 M dF508/? + 0,91 31 48
9 37 M dF508/dF508 + < 0,3 30 43
10 32 F dF508/dF508 + < 0,3 76 92
11 23 M dF508/? + < 0,3 103 99
12 37 M dF508/dF508 - < 0,3 74 101
13 34 F dF508/dF508 + 0,94 23 59
14 39 M dF508/dF508 - < 0,3 60 83
15 25 M dF508/R553x + 1,03 85,9 79,7
16 22 F dF508/N1303 + 0,9 53,6 64,6
17 43 M dF508/dF508 + < 0,3 98,8 95,5
18 23 M dF508/dF508 + 0,8 85,3 84,5
19 39 M dF508/G542x + 0,4 61 79
20 40 M dF508/? + 0,4 64 80
1 Pseudomonas aeruginosa infection
2 Normal: 80–120% of predictedRespiratory Research 2006, 7:104 http://respiratory-research.com/content/7/1/104
Page 4 of 15
(page number not for citation purposes)
The amplification products were separated by agarose gel
electrophoresis, stained with ethidium bromide and ana-
lyzed by densitometry. Densitometric data were plotted
on a log/log scale as a function of internal-standard-
derived PCR products and corrected for molar equiva-
lence.
Real-time PCR
Neutrophils exhibit low levels of mRNA in general. The
classic competitive PCR was not sensitive enough and we
had to establish real-time PCR. Real-time PCR was per-
formed by using the ABI prism 7700 sequence detector
(Perkin Elmer/Applied Biosystems). Primers and probes
were designed using the software program Primer Express
(Perkin Elmer/Applied Biosystems). For the measurement
of  β-actin, a published primers/probe set was applied
[27]. The fluorogenic probes contained a reporter dye
(FAM) covalently attached at the 5'end and a quencher
dye (TAMRA) covalently attached at the 3'end. PPARα
[Genbank: NM005036]: sense 5'-CTT CAA CAT GAA CAA
GGT CAA AGC-3', antisense 5'-AGC CAT ACA CAG TGT
CTC CAT ATC A-3', probe 5'-CGG GTC ATC CTC TCA
GGA AAG GCC-3', amplicon length 99 bp; PPARβ [Gen-
bank: L07592]: sense 5'-GGG CAT GTC ACA CAA CGC
TAT-3', antisense 5'-GCA TTG TAG ATG TGC TTG GAG
AA-3', probe 5'-CTT CTC AGC CTC CGG CAT CCG A-3',
amplicon length 147 bp; PPARγ [Genbank: D83233]:
sense 5'-GAA ACT TCA AGA GTA CCA AAG TGC AA-3',
antisense 5'-AGG CTT ATT GTA GAG CTG AGT CTT CTC-
3', probe 5'-CAA AGT GGA GCC TGC ATC TCC ACC TTA
TT-3', amplicon length 87 bp; β-actin [Genbank: D28354
and X00351]: sense 5'-AGC CTC GCC TTT GCC GA-3',
antisense 5'-CTG GTG CCT GGG GCG-3', probe 5'-CCG
CCG CCC GTC CAC ACC CGC C-3', amplicon length 174
bp.
Specific external controls were constructed for all target
genes by cloning a partial cDNA fragment (the amplicon
of interest obtained by classic PCR amplification) into a
pCR®2.1 vector (Invitrogen). A standard curve was gener-
ated: in each PCR run, 10-fold serial dilutions of the cor-
responding plasmid clone were included, with known
amounts of input copy number. In order to normalize for
inefficiencies in cDNA synthesis and RNA input amounts,
the mRNA expression of the housekeeping gene β-actin
was quantified for each sample. cDNA samples were
diluted 10 times prior to PCR amplification. PCR amplifi-
cations were performed in a total volume of 25 μl, con-
taining 5 μl cDNA sample, 12.5 μl Taqman Universal PCR
Master Mix (Perkin Elmer/Applied Biosystems), 200–800
nM of each primer and 200 nM detection probe (Eurogen-
tec). Each PCR amplification was performed in triplicate,
using the following conditions: 2 min. at 50°C and 10
min. at 95°C, followed by a total of 45 two-temperature
cycles: 15 s at 94°C and 1 min. at 60°C for PPARs and
67°C for β-actin. PCR data were analyzed through the
application of the software 'Sequence Detector 7.1' (Per-
kin Elmer/Applied Biosystems).
Western blot analysis for lymphocytes
Equal amounts (80 μg) of total cell proteins were resolved
by 10% SDS-PAGE and transferred to a PVDF membrane
(Millipore Corporation, Bedford) at 80 V for 1 hour.
Membranes were incubated with mouse PPARα mono-
clonal antibodies (1:2000 dilution) (clone B11.80A, gen-
erous gift from Dr. Winegar, Glaxo Smith Kline) at 4°C
overnight. Protein levels were normalized using a mouse
monoclonal antibody against β-actin (1:10.000 dilution)
(Sigma). Proteins were subsequently detected through the
use of horseradish peroxidase-conjugated secondary anti-
bodies and the chemiluminescence system ECL (Amer-
sham Pharmacia Biotech, Buckinghamshire, UK). After
scanning (DocuGel V-System, Scananalytics), band inten-
sities were analyzed using the software package Zero-D-
Scan™ (Scananalytics).
Immunofluorescence assay
Cytospin glass slides were prepared by centrifugation of
105 lymphocytes using a cytospin centrifuge (Cytospin 4,
Thermo Shandon). After cells were fixed in ice-cold meth-
anol and blocked with a solution of 2% BSA in PBS over-
night at 4°C, they were permeabilized with Perm/Wash
buffer (BD Biosciences Pharmingen) and then incubated
for 2 hours with monoclonal PPARα antibody, diluted
1:10 in Perm/Wash/2%BSA buffer (clone Pα B32.51
kindly provided by Dr. Winegar, Glaxo Smith Kline [28]).
After washing, the second antibody (cy3 labeled goat-anti-
mouse, Caltag) was added in a 1:250 dilution in Perm/
Wash/2%BSA buffer for 30 min. Following washing and
air-drying, the cells were embedded in Aquatex (Merck)
and evaluated by immunofluorescence microscopy.
Gel shift assay
Nuclear proteins from lymphocytes were prepared as
described by Dignam and coworkers [29]. A gel shift kit
for PPARα was obtained from Panomics, Inc. and the
instructions of the manufacturer were followed. Equal
amounts of nuclear protein extracts (10 μg as determined
by Bradford assay) were incubated for 30 min. with
biotin-labeled oligonucleotide probe, which corresponds
to the PPAR binding site, and then subjected to non-dena-
turing PAGE. Afterwards, proteins were blotted on a Pall-
BiodyneB®  (PALL Corporation) membrane and bands
were visualized after exposure to Hyperfilm™ECL (Amer-
sham Biosciences, UK). Subsequently, equal loading was
checked via Coomassie Blue staining of the membrane.
Band intensities were analyzed using the software package
Zero-D-Scan™ (Scananalytics).Respiratory Research 2006, 7:104 http://respiratory-research.com/content/7/1/104
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Statistical analysis
Results are expressed as mean ± SE. Statistical compari-
sons were made using the unpaired Student's t-test
(Sigma-plot). A value of p < 0.05 was considered signifi-
cant.
Results
Interleukin-8 levels in plasma
IL-8 in plasma was measured via ELISA to demonstrate
that the patients in this study exhibit the typical elevated
systemic cytokine levels [30]. As expected, IL-8 levels were
significantly higher in CF patients compared with control
persons (7.3 pg/ml vs 2.9 pg/ml, respectively; p < 0.03)
(Fig. 1). We can therefore assume that the inflammation
cascade is not restricted to the airways, but is also found
systemically.
PPAR mRNA expression in peripheral blood cells
In order to check for differences in the expression of
PPARs between CF patients and healthy persons, we
started screening at mRNA level. All data were normalized
to the expression levels of the housekeeping genes
GAPDH or β-actin, which were equally expressed in sam-
ples of CF patients and control persons.
Monocytes and lymphocytes
Competitive multiplex PCR products were loaded on an
agarose gel, electrophorised and stained with ethidium
bromide (see fig. 2). Bands were scanned and analyzed
with the software package Zero-D-Scan™ (Scananalytics).
PPARα
PPARα mRNA levels were significantly lower (-37%, p <
0.002) in lymphocytes of CF patients compared with con-
trol persons (Fig. 3). In monocytes, no differences were
observed in the expression of PPARα between the healthy
subjects and the CF patients (Fig. 4).
PPARβ
For both lymphocytes and monocytes, no statistical differ-
ences in the mRNA expression of PPARβ were detected
between CF patients and healthy persons (Fig. 3 and 4).
PPARγ
PPARγ mRNA was detected in a few samples of monocytes
and lymphocytes, but was not quantifiable due to the
extremely low expression levels.
Neutrophils
Neutrophils are considered end-cells as DNA and most,
but not all, mRNA and protein synthesis, cease once the
myeloid cells are mature enough to enter the blood. For
that reason, mRNA levels were rather low in neutrophils
and PPAR mRNA was difficult to quantify via the classic
competitive multiplex PCR. We therefore developed real-
time PCR, a highly sensitive and accurate method.
PPARα
PPARα mRNA levels were equal in neutrophils of CF
patients and healthy persons (Fig. 5A)
PPARβ
Idem, PPARβ mRNA levels were similar in both groups
(Fig. 5B).
PPARγ
PPARγ mRNA was detectable, but the low expression lev-
els did not allow quantification.
PPARα protein levels in peripheral blood lymphocytes 
measured via western blotting
mRNA analysis revealed less expression of PPARα in lym-
phocytes of CF patients compared with healthy persons.
On the basis of this finding we further examined the
expression of the receptor at protein level via western blot-
ting. A single band for PPARα was observed around 60
kDA (Fig. 6A). Analysis of the band intensities demon-
strated that protein levels of PPARα are significantly lower
(-26%, p < 0.05) in lymphocytes of CF patients compared
with control subjects (Fig. 6B). β-actin was measured for
normalization.
Localization of PPARα in human peripheral blood 
lymphocytes
In order to identify the subcellular localization of PPARα
within peripheral blood lymphocytes, an immunofluores-
IL-8 levels in plasma of CF patients and healthy persons  measured by ELISA Figure 1
IL-8 levels in plasma of CF patients and healthy persons 
measured by ELISA. IL-8 levels are significantly higher in CF 
patients (n = 15) than in control persons (n = 11). Results are 
shown as mean ± standard error. * Significantly different (p < 
0.03).
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cence assay was developed. As shown in Fig. 7A and 7B,
the highest concentration of the protein is observed in the
cytosol, whereas the nucleus contains only trace amounts
of the transcription factor. In the context of our study, the
technique was not found appropriate for quantifying
PPARα protein levels by means of measuring the fluores-
cence intensity. Activity was therefore measured via gel
shift assay.
Activity of the PPARα transcription factor
Since PPARα expression is lower in lymphocytes of CF
persons, it was deemed useful to check for the activity of
the transcription factor, which was determined via gel
shift assay (Fig. 8). To this end, a commercially available
kit for PPARα was used (Panomics). The DNA-binding
element (PPRE) was not radioactive-, but biotin-labeled.
Equal amounts of nuclear extracts were loaded. The meas-
urement of band intensities showed that PPARα DNA
binding activity was 36% less in lymphocytes of CF
patients, compared with control subjects (p < 0.01) (Fig.
8B). In order to evaluate the binding specificity, competi-
tion analysis was performed by adding 60-fold cold spe-
cific (PPRE) and unspecific oligonucleotide (see fig. 8A:
lane 2 and 3, respectively). The upper band fainted
strongly by adding cold PPRE, but remained unaltered
after adding cold unspecific oligonucleotide. Equal load-
ing of nuclear extracts was verified via Coomassie Blue
staining of the membrane.
sIL-2 R levels in plasma
Soluble IL-2 receptor (sIL-2R), a well-known marker for T-
lymphocyte activation, was measured in plasma of stable
CF patients and control persons via ELISA (Fig. 9). Nor-
mal values for sIL-2R levels in plasma are around 1020 pg/
ml. Statistical analysis revealed that CF patients exhibit
significantly higher levels of sIL-2R in plasma than
healthy persons (CF: 1521 ± 84.15 pg/ml vs C: 970 ±
56.44 pg/ml). These data indicate that peripheral T-lym-
phocytes of CF patients are more activated than lym-
phocytes of healthy subjects.
Discussion
The mechanisms behind the disturbed immune response
in CF are still largely unknown and require further
research. The aim of our study was to measure the expres-
sion of the PPAR transcription factors in patients with
cystic fibrosis and healthy subjects. Because of their
known regulatory functions in inflammatory processes,
RT-competitive multiplex PCR for PPARα, β, and γ and GAPDH in human peripheral blood lymphocytes Figure 2
RT-competitive multiplex PCR for PPARα, β, and γ and GAPDH in human peripheral blood lymphocytes. Picture of ethidium 
bromid stained agarose gel after electrophoresis of the amplified products. wt = wild-type amplicon, ist = internal standard 
amplicon.
Internal standard serial dilution 1:3Respiratory Research 2006, 7:104 http://respiratory-research.com/content/7/1/104
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we hypothesized that their expression and/or function
may be altered in cystic fibrosis, a disorder characterized
by an excessive host inflammatory response.
Our study confirmed that systemic inflammation was
present in our CF patients on the basis of the observed
increased levels of plasma IL-8. Our data revealed that
both PPARα mRNA and protein levels were significantly
lower in peripheral lymphocytes of CF patients than in
healthy control persons. Immunofluorescence experi-
ments demonstrated that just a small fraction of PPARα
resides in the nucleus, whereas the cytosol contains the
larger part of the transcription factor. This was observed
for both groups. Differences in activity were demonstrated
via gel shift assay, i.e. a significant reduction of PPARα
DNA binding activity in lymphocytes of CF persons com-
pared with healthy subjects. Finally, increased levels of
soluble IL-2 Receptor in plasma suggest that peripheral
lymphocytes are activated in cystic fibrosis.
Most CF patients become chronically infected with spe-
cific bacterial pathogens, such as Pseudomonas aeruginosa,
which cause a destructive inflammatory response in the
lung. However, several studies provide evidence that
inflammation can occur prior to infection and that CF
lungs are primed for inflammation [30-32]. Nevertheless,
the inflammatory processes are not restricted to the respi-
ratory tract as shown by the elevated levels of pro-inflam-
matory markers in the blood circuit of CF patients
[4,30,33]. Our study also demonstrated elevated levels of
IL-8 in plasma of CF patients. Therefore, monocytes, lym-
phocytes and neutrophils were studied, as they are impor-
tant mediators of the inflammatory response, i.a. through
the release of cytokines, chemokines, and through the
production of antibodies.
Our study revealed that PPARα and PPARβ are abun-
dantly expressed in freshly isolated monocytes and lym-
phocytes at mRNA level, whereas little or no PPARγ was
detected. Both PPARα and PPARβ mRNA could be meas-
ured via real-time PCR in neutrophils; PPARγ mRNA on
the other hand was not quantifiable. Statistical analysis
showed that PPARα mRNA, but not PPARβ mRNA, is sig-
nificantly less expressed (-37%) in lymphocytes of CF
patients compared with control persons. The same differ-
ence could be detected at protein level via western blot-
ting. The expression of PPARα and β mRNA in monocytes
and neutrophils was not significantly different in patients
and healthy persons. These data are supported by several
studies. First, there is evidence that PPARα mRNA and
PPARα and PPARβ mRNA expression levels were measured  in human peripheral blood monocytes from CF patients (CF,  n = 19; M/F: 13/6) and healthy subjects (C, n = 10; M/F: 6/4)  via RT-competitive multiplex PCR and densitometry Figure 4
PPARα and PPARβ mRNA expression levels were measured 
in human peripheral blood monocytes from CF patients (CF, 
n = 19; M/F: 13/6) and healthy subjects (C, n = 10; M/F: 6/4) 
via RT-competitive multiplex PCR and densitometry. Data 
are normalized to GAPDH mRNA expression levels. Values 
are means and standard error. Both PPAR levels were similar 
in the two groups.
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Human peripheral blood lymphocytes from CF patients (CF,  n = 15; M(ale)/F(emale): 9/6) and healthy subjects (C, n = 11;  M/F: 6/5) were subjected to RT-competitive multiplex PCR  and densitometry in order to measure PPARα and PPARβ  mRNA expression levels Figure 3
Human peripheral blood lymphocytes from CF patients (CF, 
n = 15; M(ale)/F(emale): 9/6) and healthy subjects (C, n = 11; 
M/F: 6/5) were subjected to RT-competitive multiplex PCR 
and densitometry in order to measure PPARα and PPARβ 
mRNA expression levels. Data are normalized to GAPDH 
expression levels. Values are represented as means ± stand-
ard error. PPARα expression levels were 37% lower in CF 
patients compared to control persons. ** Significantly differ-
ent (p < 0.002).
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protein expression are directly regulated by its own lig-
ands [34,35]. Fatty acids and eicosanoids, which are natu-
ral PPAR activators, are found in disturbed levels in CF
and may therefore cause a diminished expression of
PPARα. Second, PPARα expression within T-lymphocytes
is rapidly down-regulated following cellular activation
[36]. Our present study demonstrated increased plasma
soluble interleukin-2 receptor (sIL-2 R) concentrations in
CF patients, which is in line with the findings of other
research groups [37,38]. sIL-2 R is a generally accepted
marker for T-lymphocyte activation [39]. Therefore, T-
lymphocytes appear to be in some sort of activated state
in CF patients, which may be responsible for the
decreased PPARα levels. The mechanism responsible for
this down-regulation has not yet been elucidated. Third,
the pro-inflammatory cytokines IL-6, TNF-α and IL-1 have
been demonstrated to cause a reduction in the expression
of PPARα [40,41]. CF patients exhibit increased levels of
IL-2, TNF-α, IL-6 and IL-8 in sputum and serum
[4,5,32,37]. However, this can not be the major explana-
tion for the decreased PPARα levels in lymphocytes, as the
expression of the transcription factor was unaltered in
monocytes and neutrophils. And finally, an interesting
abstract by Andersson and team reported that a CF tra-
cheal epithelial cell line expressed less PPARα protein
than a normal tracheal epithelial cell line, which is com-
parable with our data [42]. The same research team found
decreased PPARγ levels in tissues specifically regulated by
CFTR in a CF mice model [43] and their data suggest that
CFTR may play a role in PPAR expression. A functional
CFTR is also expressed in lymphocytes of healthy humans.
Consequently, a defect CFTR in CF lymphocytes could
result in altered PPAR expression. In addition, research
has shown that PPAR expression may differ significantly
in target organs where inflammation occurs. For example,
a recent study reported that induction of PPARα is lacking
in the liver of CF mice compared to wild type animals fol-
lowing colitis induced bile duct injury [44].
Following our findings that PPARα expression is down-
regulated in CF lymphocytes, the question arose whether
the activity of the transcription factor was also altered.
Our immunofluorescence experiments revealed that for
both groups, the transcription factor is primarily located
in the cytosolic compartment and only a small fraction
resides in the nucleus. A similar cellular distribution was
reported in human macrophages [45] and in mice lym-
phocytes [36]. This meant that gel shift analysis had to be
applied to measure possible differences in the activity of
PPARα. The gel shifts indeed showed that PPARα DNA
binding activity was 36% lower in lymphocytes of CF
patients compared with control persons. A decreased
PPAR mRNA expression in freshly isolated human neutrophils was determined by real-time PCR for CF patients (n = 12; M/F:  7/5) and control persons (n = 12; M/F: 6/6) Figure 5
PPAR mRNA expression in freshly isolated human neutrophils was determined by real-time PCR for CF patients (n = 12; M/F: 
7/5) and control persons (n = 12; M/F: 6/6). Data are presented as the mean PPAR mRNA level relative to the β-actin mRNA 
expression [(number of PPAR copies/number of β-actin copies) × 106] and the standard error. Each measurement was per-
formed in triple. (A) PPARα mRNA expression. (B) PPARβ mRNA expression. No differences were seen between the two 
groups for both PPARα and PPARβ mRNA levels.
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DNA binding activity of PPARγ was also seen in tissues of
CFTR knock-out mice. Treatment of these mice with ros-
iglitazone, a PPARγ agonist, restored DNA binding [43].
PPARα was the first isotype recognized for its in vivo role
in inflammatory processes. Inflammation induced by leu-
kotriene B4, a PPARα ligand, has been reported to be pro-
longed in PPARα knock-out mice, suggesting an anti-
inflammatory role for PPARα [46]. Ligand-induced activa-
tion of PPARα in lymphocytes antagonized DNA binding
activity of NF-κB and decreased IL-2 and TNF-α produc-
tion [36,47], inhibited IFN-γ secretion but promoted IL-4
secretion and production [47,48]. These data indicate that
PPARα may have a significant influence on the lym-
phocytic immune response. Consequently, a decrease in
PPARα expression and function may contribute to the
excessive host inflammatory response. Our data suggest
that administration of ligands, such as the natural DHA or
synthetic fibrates, may serve as a therapy to help reduce
the inflammatory processes in CF by upregulating the
activity of PPARα (see fig. 10). Further studies need to be
carried out to test this hypothesis.
CF lung disease is well-known as a neutrophil-mediated
disease. However, as pointed out by Moss, the behavior
and biological function of lymphocytes is also altered in
CF. Lymphocytes are important immune cells because
they determine the specificity of the immune response.
Quantitative analysis of inflammatory cells in CF lung tis-
sues revealed a lymphocyte-dominated immune response
in the CF bronchial wall, beneath the surface epithelium
[1]. These lymphocytes may release cytokines, such as IL-
17, that may attract neutrophils into the airways [49,50].
CF peripheral lymphocytes also exhibit an altered pattern
in cytokine-release and production after stimulation [51-
53], which could indicate an impairment of the immune
response at the systemic level. Moreover, CF lymphocytes
are characterized by a specific incapacity to respond to P.
aeruginosa antigens [54]. Consequently, this defect could
contribute to the inability to eradicate lung infection and
inflammation due to P. aeruginosa. Summarized, the func-
tion of lymphocytes is altered in CF and they are therefore
an interesting target to be studied.
In conclusion, our study revealed that both the expression
and activity of PPARα, a transcription factor with anti-
inflammatory capacities, is down-regulated in peripheral
lymphocytes of CF patients, which may render lym-
phocytes into cells that promote the inflammatory
response and consequently lead to increased inflamma-
tion. In addition, the natural activators of PPARα are
known to be present in disturbed proportions in CF and
may therefore cause an improper activation of PPARα. We
therefore hypothesize that the expression and activity of
PPARα may be up-regulated via the administration of nat-
ural or synthetic agonists which eventually may lead to a
diminished immune response.
Abbreviations
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Western blot analysis of total protein extracts derived from  human peripheral blood lymphocytes from control persons  (C, n = 10; M/F: 4/6) and CF patients (CF, n = 11; M/F: 6/5) Figure 6
Western blot analysis of total protein extracts derived from 
human peripheral blood lymphocytes from control persons 
(C, n = 10; M/F: 4/6) and CF patients (CF, n = 11; M/F: 6/5). 
(A) A single band was detected at 60 kDa for PPARα. β-actin 
protein expression was measured for normalization. (B) 
Analysis of band intensities revealed that PPARα protein lev-
els are down-regulated (-26%) in CF patients compared to 
healthy subjects. Densitometry data are expressed as means 
± standard error. * Significantly different (p < 0.05).
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The subcellular localization of PPARα protein in freshly isolated human peripheral blood lymphocytes was determined via  immunofluorescence assay (C: n = 5 and CF: n = 5) Figure 7
The subcellular localization of PPARα protein in freshly isolated human peripheral blood lymphocytes was determined via 
immunofluorescence assay (C: n = 5 and CF: n = 5). Microscopy analysis revealed that the transcription factor is mainly situ-
ated in the small cytoplasmic area. (A) Representative immunofluorescence picture of lymphocytes derived from healthy con-
trol blood and (B) from a CF patient.
A B A B
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
VR carried out the experiments, wrote the manuscript and
participated in the study design. SL designed the multiplex
competitive PCR for PPARs, participated in the study
design and helped evaluating the results and techniques.
CS provided technical assistance. TW and DS provided the
work with critical comments. JB participated in the coor-
dination of the project and corrected the article.
Acknowledgements
The present work was supported by the Deutsche Forschungsgemein-
schaft: Internationales Graduiertenkolleg 757/1.
The authors thank Glaxo-Smith Kline, especially Dr. Winegar, for the kind 
gift of the PPARα antibodies. They also thank the patients and healthy vol-
unteers for their cooperation. Comments from Dr. Hirche are gratefully 
acknowledged.Respiratory Research 2006, 7:104 http://respiratory-research.com/content/7/1/104
Page 11 of 15
(page number not for citation purposes)
Differential PPARα binding to PPRE in peripheral lymphocytes Figure 8
Differential PPARα binding to PPRE in peripheral lymphocytes. PPARα DNA binding was analyzed via gel shift assay in periph-
eral lymphocytes of CF patients (CF, n = 11; M/F: 6/5) and healthy subjects (C, n = 11; M/F: 6/5). The DNA binding element 
was biotin-labeled. (A) A representative gel shift. Lane (-) represents the biotin-labeled DNA binding element, without the 
addition of nuclear extract. Lane 1: Lymphocytic control sample. Lane 2: Specific cold oligonucleotide binding competition 
assay: a 60-fold excess of cold synthetic PPRE was added. Lane 3: Unspecific cold oligonucleotide binding competition assay. A 
60-fold excess of unspecific synthetic oligonucleotide was used. (B) Densitometry data derived from the gel shift assays are 
expressed as means and standard error. These data show that PPARα DNA binding activity of CF patients is reduced by 36% 
compared to healthy persons. ** Significantly different (p < 0.01). On top: representative bands from a control person and a 
patient.
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sIL-2R levels were measured in plasma of CF (n = 19) and  control persons (n = 18) Figure 9
sIL-2R levels were measured in plasma of CF (n = 19) and 
control persons (n = 18). sIL-2R levels are significantly higher 
in CF patients than in control persons. Data are represented 
as mean and standard error. *** p < 0.0001.
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